This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolpin, B. M. Articles by Fuchs, C. S. Search for Related Content PubMed PubMed Citation Articles by Wolpin, B. M. Articles by Fuchs, C. S.

Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer

¹ Department of Medical Oncology, Dana-Farber Cancer Institute; ² Department of Medicine, Brigham and Women's Hospital; ³ Harvard Medical School; Departments of ⁴ Epidemiology and ⁵ Nutrition, Harvard School of Public Health; ⁶ Channing Laboratory, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School; ⁷ Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts; ⁸ Ludwig Boltzmann-Institute for Applied Cancer Research, KFJ-Spital and Applied Cancer Research, Institute for Translational Research Vienna, Vienna, Austria; ⁹ University of Washington School of Nursing, Seattle, Washington; ¹⁰ Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York; and ¹¹ Department of Medicine and Oncology, Jewish General Hospital and McGill University, Montreal, Quebec, Canada

Requests for reprints: Brian Wolpin, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-3779; Fax: 617-632-5822; E-mail: bwolpin{at}partners.org.

Insulin-like growth factor (IGF)-I has growth-promoting effects on pancreatic cancer cells, and elevated fasting serum insulin has been linked to pancreatic cancer risk. IGF binding protein-1 (IGFBP-1) is a downstream target of insulin and inhibits IGF-I activity. To investigate whether prediagnostic plasma levels of IGFBP-1 are associated with pancreatic cancer risk, we did a prospective, case-control study nested within the Health Professionals Follow-up Study, the Nurses' Health Study, the Physicians' Health Study, and the Women's Health Initiative. We assayed circulating IGFBP-1 among 144 pancreatic cancer cases that occurred 4 years after plasma collection and in 429 controls, matched for date of birth, prospective cohort, smoking status, and fasting status. When compared with participants in the three highest quartiles of plasma IGFBP-1, those in the lowest quartile experienced a relative risk (RR) for pancreatic cancer of 2.07 [95% confidence intervals (95% CI), 1.26–3.39], after adjusting for other risk factors, including circulating IGF-I, IGF binding protein-3, and C-peptide. Only participants in the lowest quartile of plasma IGFBP-1 showed an elevated risk of pancreatic cancer. The influence of low plasma IGFBP-1 became progressively stronger with time; among cases diagnosed 8 years after blood collection, the adjusted RR was 3.47 (95% CI, 1.48–8.14), comparing the bottom versus the top three quartiles. The influence of plasma IGFBP-1 was most marked among participants who never smoked cigarettes (RR, 3.30; 95% CI, 1.48–7.35). Among participants in four U.S. prospective cohort studies, low plasma IGFBP-1 levels significantly predicted an increased risk of pancreatic cancer. [Cancer Res 2007;67(16):7923–8]

This article has been cited by other articles:

				L. Jiao, A. Flood, A. F. Subar, A. R. Hollenbeck, A. Schatzkin, and R. Stolzenberg-Solomon Glycemic Index, Carbohydrates, Glycemic Load, and the Risk of Pancreatic Cancer in a Prospective Cohort Study Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1144 - 1151. [Abstract] [Full Text] [PDF]

				H. G Mulholland, L. J Murray, C. R Cardwell, and M. M Cantwell Glycemic index, glycemic load, and risk of digestive tract neoplasms: a systematic review and meta-analysis Am. J. Clinical Nutrition, February 1, 2009; 89(2): 568 - 576. [Abstract] [Full Text] [PDF]

				Y. Bao and D. S. Michaud Physical Activity and Pancreatic Cancer Risk: A Systematic Review Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2671 - 2682. [Abstract] [Full Text] [PDF]